ABUS News and Press, Arbutus Biopharma Corporation From 04/27/23

Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV activity including suppression of HBV RNA and HBsAg production in preclinical models ...

2023-04-25 11:50:13 ET Shares of Arbutus Biopharma (NASDAQ: ABUS) were trading down by 12.6% as of 11:04 a.m. ET Tuesday. The decline came after the company announced that the Food and Drug Administration (FDA) had placed a clinical hold on its Investigational New Drug (IND) applica...

2023-04-25 09:04:56 ET TRACON Pharmaceuticals ( TCON ) -51% after I-Mab gets favorable ruling in arbitration. Appreciate Holdings ( SFR ) -26% . First Republic Bank ( FRC ) -22% after Q1 earning release . Netcapital ( NCPL ) -22% . T...

WARMINSTER, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific vira...

WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its fir...

Two oral presentations scheduled for Thursday, April 27, 2023 WARMINSTER, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target sp...

2023-04-04 10:34:48 ET After straight sessions of gains, the shares of Pfizer ( NYSE: PFE ) and BioNTech ( NASDAQ: BNTX ) dropped Tuesday after Arbutus Biopharma ( NASDAQ: ABUS ) sued the COVID-19 vaccine makers over infringement of its patents related to mRNA vaccin...

Companies seek compensation for Pfizer’s and BioNTech’s unlicensed use of patented technologies in COVID-19 mRNA-LNP vaccines WARMINSTER, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biop...

Initial data expected in the second half of 2023 WARMINSTER, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics t...

Arbutus Biopharma Corporation (ABUS) Q4 2022 Earnings Conference Call March 02, 2023, 08:45 AM ET Company Participants Lisa Caperelli - VP of IR William Collier - President and CEI Michael Sofia - Chief Scientific Officer David Hastings - CFO Michael McElhaugh ...